News Releases

Taiho Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice.

Site search

2015

December 17, 2015

Taiho and Meiji Enter Into a Co-marketing Agreement in Japan for TAC-202（bilastine）, a Treatment for Allergic Disorders（PDF：554.9 KB）
November 26, 2015

NHI Reimbursement Price Listing and Launch of the Novel Antitumor Agent "Yondelis_® IV Infusion"
November 13, 2015

Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan
September 28, 2015

Novel Antitumor Agent "Yondelis_® IV Infusion" Approved in Japan for Treatment of Soft Tissue Sarcoma
September 24, 2015

Taiho Pharmaceutical Announces FDA Approval of LONSURF^® (trifluridine and tipiracil) for Refractory Metastatic Colorectal Cancer (mCRC)
September 01, 2015

The First Pre-Meal Drink in the Solmack Series "Solmack 5 Herbal Digestive Support" Nationwide Launch in Japan on Monday, September 7
June 26, 2015

ZOSYN_® Receives Approval for the Additional Indication of Febrile Neutropenia
June 15, 2015

Taiho Pharmaceutical Co., Ltd. and Servier Enter Into a License Agreement for Development and Commercialization of an Oral Anticancer Drug TAS-102 in Europe
June 01, 2015

Support for modern people in the prime of life! Designated quasi-drug Tiovita Gold α (Alpha) mini-drink to be launched throughout Japan on June 22
May 14, 2015

Results from Global Phase III Trial of TAS-102 (brand name in Japan: "Lonsurf^® ") Published in The New England Journal of Medicine
March 20, 2015

Lonsurf^® Combination Tablet for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer Receives Approval in Japan for Partial Change in Indications
March 02, 2015

Taiho Submits TAS-102 (brand name in Japan: "Lonsurf^®") Marketing Authorization Application to the European Medicines Agency for the Treatment of Refractory Metastatic Colorectal Cancer
February 23, 2015

Taiho Pharmaceutical Announces TAS-102 (brand name in Japan: "Lonsurf^®") New Drug Application for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA
January 05, 2015

Taiho Pharmaceutical Receives Approval to Manufacture and Market ZOSYN_® 4.5 for I.V. Infusion Bag, an Injectable Antibiotic Combined with β-Lactamase Inhibitor

News Releases

Select year from the Back Number